<DOC>
	<DOCNO>NCT00389545</DOCNO>
	<brief_summary>Despite widespread use effective reperfusion therapy , patient present late large myocardial infarction poor outcome . The aim study investigate safety efficacy intracoronary injection autologous bone marrow-derived mononuclear cell ( BMNCs ) patient large myocardial infarction</brief_summary>
	<brief_title>Intracoronary Stem Cells Large Myocardial Infarction</brief_title>
	<detailed_description>In current era , 30 % patient ST-segment elevation myocardial infarction , usually present late , show ongoing leave ventricular ( LV ) remodel poor clinical outcome despite primary percutaneous coronary intervention ( PCI ) . Cardiac transfer bone marrow-derived stem progenitor cell investigate adjunctive therapy promote regeneration infarcted myocardium . Therefore , design multicenter , randomize study test safety efficacy intracoronary injection autologous BMNCs patient large acute anterior myocardial infarction late presentation , treat successful primary PCI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Patients first STsegment elevation acute anterior myocardial infarction due occlusion proximal leave anterior ascend coronary artery ( LAD ) , underwent successful primary stented PCI . Patients eligible primary PCI 4 12 hour symptom onset show reduce LV ejection fraction ≤ 45 % least 3 akinetic segment LAD perfusion territory echocardiogram perform 24 hour PCI . Exclusion criterion age ≥ 80 year , cardiogenic shock ( Killip IV ) , multivessel coronary artery disease , serious renal hepatic disease , blood cell disorder , document cancer terminal illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>